REPLY
8.3.2024 09:31:35 CET | Business Wire | Press release
Reply has been ranked among the leading providers of "Salesforce-related Services in Europe 2024" in the PAC Innovation RADAR, an industry study by the independent research and consulting company PAC. In the report, Reply received the highest "Best in Class" award in five industries: Energy & Utilities, Financial Services, Communication & Media, Retail and Manufacturing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240308650974/en/
The PAC INNOVATION RADAR is an instrument for the holistic evaluation of software and ICT service providers from the independent research and consulting company PAC. In the PAC INNOVATION RADAR for Salesforce-related services in Europe, Reply was awarded "Best in Class" in five sectors. (Photo: Business Wire)
The study evaluates the service performance of international software and ICT service providers implementing Salesforce projects in specific IT market segments. Based on pre-defined criteria, PAC analyzes the strategy, development, and market position of the providers and assesses their performance and competencies. For IT decision makers, the PAC RADAR provides valuable guidance in selecting the appropriate service partner.
In the Energy & Utilities, Financial Services, Communication & Media, Retail and Manufacturing sectors, Reply was once again awarded "Best in Class" for its outstanding expertise and market strength in Salesforce-related services. A Salesforce partner since 2005, Reply uses the Salesforce platform to implement effective, customised cloud solutions to ensure customer success worldwide.
Thanks to its companies highly specialised in Salesforce technology, Arlanis Reply, Open Reply, Retail Reply and Power Reply, and more than 900 Salesforce certifications, Reply's competencies cover the entire Salesforce offering: Sales, Service and Marketing, B2B and B2C Commerce, Integration with Mulesoft and Analytics with Tableau. In addition, Reply's experts work with Salesforce extensions for CPQ, Field Service Lightning, Pardot and Einstein AI.
Nick Mayes, Principal Analyst at PAC, commented: "Reply is intensively exploring the market potential of generative AI for enterprises and offers strong expertise in the field of AI and Chat GPT. As a result, Reply has been able to implement innovative Salesforce GPT applications to support the needs of different industry sectors, in a very short time. Reply is leading the development of Salesforce's AI portfolio, creating new business models, products and services for enterprises.”
Filippo Rizzante, CTO of Reply, added: "Reply has an agile and integrated approach to developing cloud-native solutions. Our international teams use the latest technologies, such as AI, to optimise the customer experience and implement projects that have a proven impact on the business success of companies."
Reply has already been named an "EMEA Strategic Partner" by Salesforce in 2023. This designation is given by Salesforce to partner companies that are committed to working across regions and driving strategic issues such as generative AI together with Salesforce. Moreover, Reply is one of the few Salesforce experts in the automotive sector worldwide and has been confirmed by Salesforce as an "Automotive Cloud Launch Partner."
About PAC Innovation RADAR: "Leading Providers of Salesforce-related services in Europe 2024"
Reply
Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
PAC
PAC is the leading European consulting and analyst firm for the IT industry, a content-based company with a consulting DNA. We accompany software & IT service vendors worldwide on their growth journey. Since 1976, we have helped our clients to understand market dynamics, grow their revenue, and raise their profile. PAC is an analyst-led consultancy with a team of over 100 experts across Europe. We provide market research and analysis on more than 30 countries worldwide, delivered through our portfolio pillars, Guidance, Insights, and Visibility, and our renowned SITSI® research platform. www.pacanalyst.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240308650974/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom